Sugi Predict

Sugi Predict / Compounds / SCHEMBL1779020

SCHEMBL1779020

SCHEMBL1779020

N=C(N)NCCC[C@H](NC(=O)CNC(=O)[C@@H](N)CCC(=O)O)C(=O)Nc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDF Q9HBH1 1/20 0.42
▸ LTA4H P09960 3/20 0.41
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SSTR3 P32745 1/20 0.38
▸ S1PR1 P21453 1/20 0.37
▸ S1PR3 Q99500 1/20 0.37
▸ NPY4R P50391 8/20 0.37
▸ NPY1R P25929 5/20 0.37
▸ NPY2R P49146 5/20 0.37
▸ NPY5R Q15761 5/20 0.37
▸ MMP2 P08253 1/20 0.36
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA4 P22748 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15923684 1.00 PDF (0.42) PDFLTA4HMEN1ALDH1A1CYP2C9
SCHEMBL5582797 0.94 PDF (0.44) PDFMEN1ALDH1A1KMT2ASSTR3
SCHEMBL15286730 0.94 PDF (0.44) PDFMEN1ALDH1A1KMT2ASSTR3
Hydrochloric Acid SCHEMBL4449414 0.93 PDF (0.44) PDFMEN1ALDH1A1KMT2ASSTR3
SCHEMBL38651683 0.90 PDF (0.51) PDFMEN1ALDH1A1KMT2ASSTR3
SCHEMBL30073980 0.88 SSTR3 (0.47) PDFMEN1ALDH1A1KMT2ASSTR3
SCHEMBL1780776 0.88 PDF (0.46) PDFMEN1ALDH1A1KMT2ASSTR3
SCHEMBL8582382 0.87 PDF (0.45) PDFMEN1ALDH1A1KMT2ASSTR3
SCHEMBL5178304 0.87 PDF (0.42) PDFMEN1ALDH1A1CYP2C9HPGD
SCHEMBL5756647 0.86 PDF (0.45) PDFMEN1ALDH1A1KMT2ASSTR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4740954-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME WITH LEKTI EXPRESSING RECOMBINANT MICROBES AZITRA, INC. (US) 2026-05-13 — — EP disclosed
EP-3638369-B1 COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME WITH LEKTI EXPRESSING RECOMBINANT MICROBES AZITRA INC (US) 2026-04-29 — — EP disclosed
US-12606610-B2 Compositions and methods for treatment of Netherton Syndrome with LEKTI expressing recombinant microbes AZITRA INC (US) 2026-04-21 — — US disclosed
EP-4720326-A1 RECOMBINANT AMEBOCYTE CLOTTING FACTORS AND USES THEREOF Charles River Laboratories, Inc. (US) 2026-04-08 — — EP disclosed
CN-114846136-B Recombinant factor G derived from horseshoe crab and method for assaying beta-glucan using the same 富士胶片株式会社 2024-07-12 — — CN disclosed
US-20240218049-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME WITH LEKTI EXPRESSING RECOMBINANT MICROBES AZITRA INC (US) 2024-07-04 — — US disclosed
US-20240125789-A1 HYBRID AMEBOCYTE LYSATE AND USES THEREOF CHARLES RIVER LABORATORIES, INC. (US) 2024-04-18 — — US disclosed
EP-4291648-A1 HYBRID AMEBOCYTE LYSATE AND USES THEREOF Charles River Laboratories, Inc. (US) 2023-12-20 — — EP disclosed
US-11773154-B2 Compositions and methods for treatment of Netherton Syndrome with LEKTI expressing recombinant microbes AZITRA INC (US) 2023-10-03 — — US disclosed
US-20230258647-A1 HYBRID AMEBOCYTE LYSATE AND USES THEREOF JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT 2023-08-17 — — US disclosed
WO-2022174082-A1 HYBRID AMEBOCYTE LYSATE AND USES THEREOF CHARLES RIVER LABORATORIES, INC. (US) 2022-08-18 — — WO disclosed
EP-3986453-A1 ANTI- PROTEASE NEXIN-1 CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2022-04-27 — — EP disclosed
CN-114206938-A Anti-protease NEXIN-1 conformational single domain antibodies and uses thereof 国家医疗保健研究所 2022-03-18 — — CN disclosed
US-7943333-B2 Diagnostic method for identifying carriers of the Marburg I variant of factor VII-activating protease (FSAP) on the basis of differential modulation of FSAP activity SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH (DE) 2011-05-17 — — US disclosed
US-20070190574-A1 Diagnostic method for identifying carriers of the Marburg I variant of factor VII-activating protease (FSAP) on the basis of differential modulation of FSAP activity DADE BEHRING MARBURG GMBH 2007-08-16 — — US disclosed
EP-1817109-A1 MIXED-MODAL ANION-EXCHANGE TYPE SEPARATION MATERIAL Merck Patent GmbH (DE) 2007-08-15 — — EP disclosed
WO-2006058623-A1 MIXED-MODAL ANION-EXCHANGE TYPE SEPARATION MATERIAL MERCK PATENT GMBH (DE) 2006-06-08 — — WO disclosed
US-5637503-A CULTURE PRODUCT GRUENENTHAL GMBH (DE) 1997-06-10 — — US disclosed
US-4999194-A Fibrin specific, anticoagulatants COLLABORATIVE RESEARCH, INC. (US) 1991-03-12 — — US disclosed
US-4835253-A LOW MOLECULAR WEIGHT KININOGEN ANALOGS THE UNIVERSITY HOSPITAL (US) 1989-05-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12606610-B2 Compositions and methods for treatment of Netherton Syndrome with LEKTI expressing recombinant microbes CUTA, TMPRSS11D, KLK5 PDF 2001/4885LTA4H 230/4885MEN1 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.